Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
R PietschnerJ KolwelterA BoschK StriepeS JungD KannenkerilC OttM SchifferS AchenbachRoland Erich SchmiederPublished in: Cardiovascular diabetology (2021)
In patients with stable CHF ketone bodies as assessed by β-OHB increased after treatment with empagliflozin. This increase led to an attenuation of the beneficial effects of empagliflozin on BP and vascular parameters. Trial registration The study was registered at http://www.clinicaltrials.gov (NCT03128528).